Serum biomarkers confirming stable remission in inflammatory bowel disease
Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in individual...
Verfasser: | |
---|---|
FB/Einrichtung: | FB 05: Medizinische Fakultät
FB 13: Biologie |
Dokumenttypen: | Artikel |
Medientypen: | Text |
Erscheinungsdatum: | 2021 |
Publikation in MIAMI: | 11.05.2023 |
Datum der letzten Änderung: | 11.05.2023 |
Angaben zur Ausgabe: | [Electronic ed.] |
Quelle: | Scientific Reports 11 (2021), 6690, 1-10 |
Schlagwörter: | Biomarkers; Inflammatory bowel disease; Prognostic markers |
Fachgebiet (DDC): | 610: Medizin und Gesundheit |
Lizenz: | CC BY 4.0 |
Sprache: | English |
Förderung: | Finanziert über die DEAL-Vereinbarung mit Wiley 2019-2022. Förderer: European Commission / Projektnummer: 305266 |
Format: | PDF-Dokument |
URN: | urn:nbn:de:hbz:6-90039665445 |
Weitere Identifikatoren: | DOI: 10.17879/50049635721 |
Permalink: | https://nbn-resolving.de/urn:nbn:de:hbz:6-90039665445 |
Verwandte Dokumente: |
|
Onlinezugriff: | 10.1038_s41598-021-86251-w.pdf |
Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in individual patients. We investigated blood-based biomarkers for the confirmation of disease remission in patients with IBD. We retrospectively analyzed samples of 40 IBD patients (30 UC, 10 CD) enrolled in a tight-control follow-up study. Half of the patients had a flare during follow up. Serum was analyzed for S100A12 as well as S100A8/A9 and for 50 further biomarkers in a bead-based multiplex assay. The concentrations of 9 cytokines/chemokines and S100A8/A9 significantly differed in IBD patients with unstable remission (before flares) when compared to IBD patients with stable remission. Although the number of patients was small, ROC curve analyses revealed a number of biomarkers (IL-1β, IL-1RA, IL-8, IL13, IL-15, IL-21, IL-25, IFN-β, CXCL9, CXCL10, CXCL11, Galectin-1, G-CSF and S100A8/A9) that were elevated in patients with later occurring relapses. While earlier studies on peripheral biomarkers in IBD are limited to only few analytes, our study using a broad screening approach identified serum biomarkers with the potential to indicate unstable disease control in IBD, which may help to steer individual therapies to maintain remission.